Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

This study has been completed.
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Sandoz
ClinicalTrials.gov Identifier:
NCT01274182
First received: January 10, 2011
Last updated: December 5, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)